Article
Officials from the FDA have cleared an investigational new drug (IND) application for BW-1010 (BlueWillow Biologics), according to the company. The drug would be the company’s next-generation anthrax vaccine candidate.
Officials from the FDA have cleared an investigational new drug (IND) application for BlueWillow Biologics' BW-1010 vaccine, according to the company. The drug would be the company’s next-generation anthrax vaccine candidate.
A Phase 1 clinical study is expected to begin enrollment this year, with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine combines a novel intranasal NanoVax system with recombinant protective antigen (rPA) for anthrax. The new drug’s platform employs a proprietary oil-in-water nanoemulsion adjuvant that provokes both systemic and mucosal immunity. This combination enables protection against challenging respiratory infections, like anthrax.
Anthrax is listed as a Category A priority pathogen by NIAID, which means that the disease poses the highest possible risk to national security and public health. The anthrax-causing bacteria can cause severe illness or death when entering the body through inhalation, ingestion, or cuts in the skin.
The currently licensed injectable vaccine requires 3 immunizations, along with antimicrobial therapy as a medical countermeasure following potential anthrax exposure.
REFERENCE
BlueWillow receives FDA clearance to begin phase 1 study of its intranasal anthrax vaccine [news release]. Ann Arbor, MI; October 23, 2019: BlueWillow Biologics. https://prnmedia.prnewswire.com/news-releases/bluewillow-receives-fda-clearance-to-begin-phase-1-study-of-its-intranasal-anthrax-vaccine-300943726.html. Accessed October 23, 2019.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Clesrovimab Receives FDA Approval for RSV Lower Respiratory Tract Prevention in Infants